Evidence map›Paper›PMID 38935293›Full record

ArticleDermatologie (Heidelberg, Germany)2024

[Rehabilitation for patients with chronic pruritus].

Tilmann Peter Voigt, Athanasios Tsianakas

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Dermatologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tilmann Peter VoigtFachklinik Bad Bentheim, Klinik für Dermatologie und Allergologie, Am Bade 1, 48455, Bad Bentheim, Deutschland.
Athanasios TsianakasFachklinik Bad Bentheim, Klinik für Dermatologie und Allergologie, Am Bade 1, 48455, Bad Bentheim, Deutschland. a.tsianakas@fk-bentheim.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor a long time, chronic pruritus was considered difficult to treat. Modern therapy options and detailed guidelines have created new opportunities for patients to improve their quality of life. However, due to the complexity of the disease, the need for multimodal treatment remains.

objectivesThis article aims to investigate whether dermatological rehabilitation offers additional benefits to those affected and whether it should therefore be part of the treatment concept for chronic pruritus.

methodsAfter introduction of the pruritus program of a rehabilitation clinic, a prospective study is presented that focuses on the patient-relevant benefits of therapy. It used standardized questionnaires to record pruritus intensity, the presence of depression, anxiety, itch-related limitations, and quality of life in patients with chronic pruritus before and after rehabilitation.

resultsOf the patients surveyed, 91.7% achieved a patient-relevant benefit through rehabilitation. Pruritus intensity, depression, anxiety, itch-related limitations, and restrictions on quality of life decreased significantly. Almost half of all participating patients had been initially diagnosed more than 10 years ago.

conclusionsDermatological rehabilitation with a multimodal concept for the treatment of chronic pruritus can help affected patients and should be part of the therapy concept. This should be done as early as possible before the disease progresses over a long period of time and makes treatment more difficult.

Indexed as

PruritusQuality of LifeAnxietyChronic DiseaseCombined Modality TherapyDepressionHumansSurveys and QuestionnairesTreatment OutcomeClinical evaluationDermatological rehabilitationItchingMultimodal treatmentQuality of life

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.